Market Highlights
Global Intracranial Hemorrhage Diagnosis & Treatment Market Share is expected to register a CAGR of 5.98% during the forecast period and is expected to hit USD 2,349.59 Million by 2027.
Intracranial hemorrhage is a serious medical emergency that can be caused due to the buildup of blood within the skull. This can lead to an increase in intracranial pressure, which can further damage brain tissues. Intracerebral hemorrhage (ICH) is a form of intracranial bleed that occurs in the brain or in the ventricles, also called the cerebral bleed. Subarachnoid bleeding (SAH) is a form of life-threatening stroke resulting from bleeding in the brain environment. An epidural hematoma (EDH) is bleeding between the inside of the skull and the brain’s outer covering (called the dura). A skull fracture often causes an EDH during childhood or adolescence.
The growing prevalence of aneurysms, the increasing number of road accidents, and the increasing expenditure on healthcare infrastructure are anticipated to drive the global intracranial hemorrhage diagnosis & treatment market. In addition, an increase in research funding for the treatment of intracranial hemorrhage further drives the growth of the market. For instance, Oslo University Hospital, Norway, is evaluating the effects of antithrombotic drugs for the prevention of ischemic events in patients with recent intracerebral hemorrhage. However, increasing counterfeit drugs & side effects of the treatment, and lack of skilled workforce are expected to restrict the market growth.
Get Free Sample PDF Brochure @ https://www.marketresearchfuture.com/sample request/3687
Segment Analysis
Global Intracranial Hemorrhage Diagnosis & Treatment Market has been divided based on Type and Diagnosis & Treatment.
The market, based on type, has been segregated into intracerebral hemorrhage, subarachnoid hemorrhage, epidural hematoma, and subdural hematoma.
Based on diagnosis & treatment, the intracranial hemorrhage diagnosis & treatment market has been divided into diagnosis and treatment. The diagnosis segment has been further sub-segmented into CT, MRI, and others. The treatment segment is further sub-segmented into medication and surgery. Based on medication, the market is further sub-segmented into anti-hypertensive drugs, coagulants, and others, whereas based on surgery, the market is sub-segmented into decompression surgery, craniotomy with open surgery, endoscopic evacuation, stereotactic aspiration, and clipping or coiling procedures.
Regional Analysis
Global Intracranial Hemorrhage Diagnosis & Treatment Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa. The Americas is likely to hold the largest share of the global intracranial hemorrhage diagnosis & treatment market during the assessment period due to the well-developed healthcare sector, research spending, rapid adoption of advanced treatment, and leading players in the region. Moreover, integration of clinical data to understand the prognosis of intracranial hemorrhage and treatment options is anticipated to fuel the research activities in the region. For instance, The Radiological Society of North America’s (RSNA) 2019 Brain CT Hemorrhage Challenge aims to construct a machine learning dataset.
The Europe market is expected to register substantial growth in the market owing to the easy accessibility to advanced treatment facilities, rising government initiatives to promote research, increasing number of trauma cases, and growing healthcare expenditure.
Asia-Pacific is estimated to be the fastest-growing region globally due to increasing R&D funding by developing countries such as China and India for the development of the healthcare infrastructure. The intracranial hemorrhage diagnosis & treatment market in Middle East & Africa is expected to witness gradual growth due to developing healthcare infrastructure.
Key Players
MRFR recognizes the following companies as the Key Players in the Global Intracranial Hemorrhage Diagnosis & Treatment Market— Canon Inc. (Japan), FUJIFILM Holdings Corporation (Japan), GE Healthcare (US), Hitachi Ltd. (Japan), Infrascan, inc. (US), Johnson & Johnson (US), Koninklijke Philips N.V. (Netherlands), Medtronic plc (Ireland), Siemens AG (Germany), and Stryker Corporation (US).
Key Findings of the Study
- Global Intracranial Hemorrhage Diagnosis & Treatment Market was valued at USD 1,493.98 Million in 2019 and is expected to register a CAGR of 5.98% during the assessment period.
- The Americas accounted for the largest share of the global market owing to well-developed healthcare sector, research spending, rapid adoption of advanced treatment, and the presence of leading players in the region.
- Based on the type, the intracerebral hemorrhage segment accounted for the largest market share of 42.72% in 2019.
- Based on diagnosis & treatment, the diagnosis segment is expected to register the fastest growth at a CAGR of 6.07% during the forecast period.
- Based on the treatment, the medication segment accounted for the largest market share with a value of USD 330.32 Million in 2019.
Access Report Details @ https://www.marketresearchfuture.com/reports/intracranial-hemorrhage-diagnosis-and-treatment-market-3687
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
Contact:
Market Research Future®
99 Hudson Street,5Th Floor
New York, New York 10013
United States of America
